Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Avalo Therapeutics (AVTX) Change in Account Payables (2016 - 2025)

Historic Change in Account Payables for Avalo Therapeutics (AVTX) over the last 12 years, with Q3 2025 value amounting to -$1.9 million.

  • Avalo Therapeutics' Change in Account Payables fell 26352.64% to -$1.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$1.3 million, marking a year-over-year decrease of 23069.4%. This contributed to the annual value of -$163000.0 for FY2024, which is 9330.87% up from last year.
  • Per Avalo Therapeutics' latest filing, its Change in Account Payables stood at -$1.9 million for Q3 2025, which was down 26352.64% from $1.7 million recorded in Q2 2025.
  • Over the past 5 years, Avalo Therapeutics' Change in Account Payables peaked at $9.3 million during Q1 2021, and registered a low of -$9.7 million during Q2 2021.
  • Moreover, its 5-year median value for Change in Account Payables was $37000.0 (2023), whereas its average is -$110473.7.
  • Examining YoY changes over the last 5 years, Avalo Therapeutics' Change in Account Payables showed a top increase of 362071.71% in 2021 and a maximum decrease of 565178.57% in 2021.
  • Avalo Therapeutics' Change in Account Payables (Quarter) stood at -$198000.0 in 2021, then surged by 824.75% to $1.4 million in 2022, then plummeted by 123.83% to -$342000.0 in 2023, then crashed by 346.78% to -$1.5 million in 2024, then dropped by 23.82% to -$1.9 million in 2025.
  • Its last three reported values are -$1.9 million in Q3 2025, $1.7 million for Q2 2025, and $398000.0 during Q1 2025.